Skip to main content
Menu
US
car-t-cell-1920x400.jpg
Literature - Publication Review

Monitoring CAR-T cells activation and their cytotoxicity

CAR-T cells - a new immunotherapy strategy used in the destruction of tumor cells

CAR-T cells (for T cells carrying a chimeric receptor) are involved in gene therapies. The cells are made from the individual's own T-lymphocytes. When genetically modified and reinjected, they are capable of specifically recognizing and destroying cancer cells after binding to the tumor antigen by releasing a mixture of cytokines and pro-inflammatory chemokines.

This literature review, based on several scientific publications, focuses on the activation of CAR-T cells in vitro, monitored by using our homogeneous technologies such as AlphaLISA™ and HTRF™. These research methods are simple and robust, while consuming a minimum of samples and providing results faster than ELISA tests.

See below the different points monitored by our technologies in this literature review:

  • Measurement of cell proliferation and cytokine release
  • Cytotoxicity tests: DELFIA Eu TDA in CAR-T co-culture
  • Cytotoxicity percentage measurement of CD19-expressing target cell lines
  • Measurement of IFN concentrations-γ

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Monitoring CAR-T cells activation and their cytotoxicity